GSK plc 6-K, filed Feb 23, 2023
GSK plc (GSK)
6-K
2023-02-23
For: 2023-02-23
View Original
Added on
July 04, 2026
About this 6-K
GSK plc filed this 6-K on February 23, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of February 2023
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
ViiV Healthcare announces positive
data demonstrating long-acting injectable Cabenuva (cabotegravir, rilpivirine) is as effective
as daily oral Biktarvy (BIC/FTC/TAF) for the treatment of
HIV-1
● 12-month
findings from the SOLAR study showed that the every-two-month
regimen of CAB+RPV LA demonstrated non-inferior
efficacy compared to continuation of daily oral
BIC/FTC/TAF
● 90%
of participants who switched from BIC/FTC/TAF to CAB+RPV LA
preferred the complete long-acting regimen to daily
pills
London, 23 February 2023 - ViiV Healthcare, the global specialist HIV
company majority owned by GSK, with Pfizer and Shionogi as
shareholders, announced yesterday positive 12-month findings from
the SOLAR study. SOLAR is the first head-to-head, Phase IIIb study
of the first and only complete long-acting injectable
regimen Cabenuva (cabotegravir, rilpivirine [CAB+RPV LA])
compared against complete daily oral
regimen Biktarvy (bictegravir/emtricitabine/tenofovir
alafenamide [BIC/FTC/TAF]).
Study findings showed that CAB+RPV LA dosed every two months
achieved the primary endpoint of non-inferior virologic efficacy
versus daily oral BIC/FTC/TAF, while 90% of participants who
switched to CAB+RPV LA from BIC/FTC/TAF, and who completed a survey
(n=425), preferred the long-acting regimen. Switching to CAB+RPV LA
from BIC/FTC/TAF during the SOLAR study was efficacious,
well-tolerated, and improved treatment satisfaction from baseline
based on adjusted HIV Treatment Satisfaction Questionnaire status
version scores (HIVTSQs). These data were presented at
the 30th Conference
on Retroviruses and Opportunistic Infections
(CROI), being held in Seattle,
Washington.
Harmony P. Garges, M.D., MPH, Chief Medical Officer at ViiV
Healthcare, said: "The
treatment needs of people living with HIV are changing, with ample
evidence on patient preference suggesting some people living
with HIV can experience challenges with taking daily oral treatment
for HIV. It's essential that people living with HIV have treatment
options that can help alleviate these burdens and we believe that
complete long-acting regimens are here to help address some of
those challenges today. We are confident that cabotegravir, as part
of a complete long-acting regimen, is a cornerstone for the
long-acting treatment era in HIV medicine, as supported by its
strong and durable efficacy, safety, and by the fact that 90% of
participants in this study who completed a survey preferred a
long-acting regimen after switching from their daily oral
pills."
In the SOLAR study, 670 participants who were virally supressed and
taking BIC/FTC/TAF were randomised 2:1 to switch to CAB+RPV LA
administered every two months (447 participants) or continue taking
daily oral BIC/FTC/TAF (223 participants). The SOLAR study met its
primary endpoint at Month 12, when CAB+RPV LA demonstrated
non-inferior efficacy versus daily oral BIC/FTC/TAF based on the
proportion of participants with HIV-1 RNA ≥50 c/mL using
the FDA Snapshot algorithm and a 4% non-inferiority margin (mITT-E;
CAB+RPV LA: 5/447 [1%], BIC/FTC/TAF: 1/223 [<1%], adjusted
difference: 0.7%, 95% confidence interval [-0.7, 2.0]). The study
found that rates of virologic suppression (HIV-1 RNA <50 c/mL)
were similar between treatment arms (CAB+RPV LA: 403/447 [90%],
BIC/FTC/TAF: 207/223 [93%], adjusted difference: -2.7%, 95%
confidence interval [-7.0, 1.7]). Non-inferior virologic outcomes
were confirmed in the ITT-E and Per Protocol (PP)
analyses.
At the beginning of the study, 47% of participants reported
always or often experiencing one or more challenges with taking
their daily therapy, including "being worried about people
unintentionally discovering their HIV status," "being worried about
forgetting to take their HIV medication," or "feeling that taking
their HIV medication was an uncomfortable reminder of their HIV
status." Mean treatment satisfaction scores (HIVTSQs) improved
significantly at the conclusion of the study for participants
taking CAB+RPV LA (+3.36) compared to BIC/FTC/TAF (-1.59) from
baseline (CAB+RPV LA: 57.88, BIC/FTC/TAF: 58.38) (p<0.001). 90%
of participants who switched to CAB+RPV LA and completed the
survey, preferred long-acting therapy versus daily oral pills
(n=382/425), with the top five reasons for preferring long-acting
therapy being:
● I don't have to worry as much about
remembering to take HIV medication every day
● It is more convenient for me to receive
injections every 2 months
● I do not have to carry my HIV medication
with me
● I do not have to think about my HIV status
every day
● I do not have to worry about others seeing
or finding my HIV pills
Confirmed virologic failure (CVF) was infrequent. Two participants
(0.4%) in the mITT-E analysis and one additional participant in the
ITT-E analysis who received CAB+RPV LA, developed CVF, with
subsequent identification of resistance-associated mutations (RAMs)
to NNRTI and integrase inhibitors. No participant in the
BIC/FTC/TAF treatment arm developed CVF.
Treatment with CAB+RPV LA and BIC/FTC/TAF were both well-tolerated.
With the exclusion of injection site reaction (ISRs), adverse
events (AEs) and serious adverse events (SAEs) were comparable
between arms, although drug-related AEs were more frequent in the
long-acting (the switch) arm (20% vs <1%). The most
commonly reported drug-related AEs in the LA arm were pyrexia (3%),
headache (2%), fatigue (2%), and diarrhoea (2%). In the
BIC/FTC/TAF arm, the two drug-related AEs reported were weight gain
(<1%) and abnormal hepatic function (<1%). Most ISRs in
the long-acting arm were Grade 1 or 2 (98%) and short lived (median
3 days), with few participants discontinuing due to
injection-related reasons (2%). More participants in the
long-acting arm withdrew due to AEs (6% vs <1%).
Moti N. Ramgopal of the Midway Immunology and Research Center, Fort
Pierce, Florida and Principal Investigator for SOLAR,
said: "There are many
people living with HIV who are virally suppressed but experience
challenges taking a daily oral pill, including fears of
accidentally disclosing their HIV status due to discovery of
their medicine. The SOLAR findings demonstrate that CAB+RPV LA
administered every two months is as effective as BIC/FTC/TAF, while
also addressing some important challenges associated with taking
daily HIV treatment. These findings raise the critical reminder
that healthcare providers who prescribe HIV medicines should
identify and incorporate patient preferences when making treatment
recommendations, in addition to standard efficacy and safety data,
to ensure that people living with HIV have the best treatment
option for their needs."
ViiV Healthcare's cabotegravir in combination with rilpivirine, a
product of Janssen Sciences Ireland Unlimited Company, one of the
Janssen Pharmaceutical Companies of Johnson & Johnson, was
co-developed as part of a collaboration with Janssen and builds on
ViiV Healthcare's industry-leading long-acting portfolio that is
centred on delivering innovative medicines for the HIV community.
The complete long-acting regimen of CAB+RPV LA is licensed in
Canada, USA and Australia under the brand
name Cabenuva, and in Europe and Japan
as Vocabria (cabotegravir injection and tablets)
and Rekambys (rilpivirine long-acting injectable
suspension). Additional findings and analyses from the SOLAR study,
including additional data on patient reported outcomes, will be
presented at future congresses.
About SOLAR
SOLAR (NCT04542070) is a Phase IIIb, randomised (2:1),
open-label, multicentre, non-inferiority (NI) study assessing
switching virologically suppressed adults to CAB+RPV LA
(with/without oral lead-in [OLI]) dosed every two months versus
continuing BIC/FTC/TAF. The primary analysis was based on the
pre-specified modified intent-to-treat exposed (mITT-E) population
(n=11 excluded from the ITT-E for major protocol deviations). The
primary endpoint was the proportion with plasma HIV-1
RNA ≥50 c/mL (FDA Snapshot, 4% NI margin) at M11 (LA
without oral lead-in)/M12 (LA with oral lead-in and BIC/FTC/TAF).
Other endpoints were the proportion with plasma HIV-1 RNA <50
c/mL (FDA Snapshot, -12% NI margin), incidence of confirmed
virologic failure (CVF; 2 consecutive HIV-1 RNA ≥200 c/mL),
safety, tolerability, treatment satisfaction (HIVTSQs), and
preference.
About Cabenuva (cabotegravir,
rilpivirine)
Cabenuva is indicated as a
complete regimen for the treatment of HIV-1 infection in adults to
replace the current antiretroviral regimen in those who are
virologically suppressed (HIV-1 RNA <50 c/ml) on a stable
antiretroviral regimen with no history of treatment failure and
with no known or suspected resistance to either cabotegravir or
rilpivirine.
The complete regimen combines the integrase strand transfer
inhibitor (INSTI) cabotegravir, developed by ViiV Healthcare, with
rilpivirine, a non-nucleoside reverse transcriptase inhibitor
(NNRTI) developed by Janssen Sciences Ireland Unlimited Company.
Rilpivirine is approved in the US as a 25mg tablet taken once a day
to treat HIV-1 in combination with other antiretroviral agents in
antiretroviral treatment-naïve patients 12 years of age and
older and weighing at least 35kg with a viral load ≤100,000
HIV RNA c/ml.
INSTIs inhibit HIV replication by preventing the viral DNA from
integrating into the genetic material of human immune cells
(T-cells). This step is essential in the HIV replication cycle and
is also responsible for establishing chronic disease. Rilpivirine
is an NNRTI that works by interfering with an enzyme called reverse
transcriptase, which stops the virus from multiplying.
Trademarks are owned by or licensed to the ViiV Healthcare group of
companies.
Please consult the full Prescribing
Information.
About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in
November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to
delivering advances in treatment and care for people living with
HIV and for people who are at risk of acquiring
HIV. Shionogi became
a ViiV shareholder in October 2012. The company's aims are to take
a deeper and broader interest in HIV and AIDS than any company has
done before and take a new approach to deliver effective and
innovative medicines for HIV treatment and prevention, as well as
support communities affected by HIV.
For more information on the company, its management, portfolio,
pipeline, and commitment, please visit www.viivhealthcare.com.
About GSK
GSK is a global biopharma company with a purpose to unite
science, technology, and talent to get ahead of disease together.
Find out more at gsk.com/company
|
ViiV Healthcare enquiries:
|
|
|
|
|
Media enquiries:
|
Rachel Jaikaran
|
+44 (0) 7823 523 755
|
(London)
|
|
|
Audrey Abernathy
|
+1 919 605 4521
|
(North Carolina)
|
|
GSK enquiries:
|
|
|
|
|
Media enquiries:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Dan Smith
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
Lyndsay Meyer
|
+1 202 302 4595
|
(Washington DC)
|
|
|
Alison Hunt
|
+1 540 742 3391
|
(Washington DC)
|
|
|
|
|
|
|
|
|
|
|
|
Investor Relations:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Josh Williams
|
+44 (0) 7385 415719
|
(London)
|
|
|
Camilla Campbell
Steph Mountifield
Jeff McLaughlin
|
+44 (0) 7803 050238
+44 (0) 7796 707505
+1 215 751 7002
|
(London)
(London)
(Philadelphia)
|
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
|
|
|
|
|
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK's Q4 Results for 2022 and
any impacts of the COVID-19 pandemic.
Registered in England & Wales:
GSK plc ViiV
Healthcare Limited
No. 3888792
No. 06876960
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: February
23, 2023
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|